Fig. 3

PMBC immunophenotypic differences were observed according to response to neoadjuvant chemotherapy (NAC) in TNBC and luminal breast cancers. (A) Density plots showing lower density of myeloid cells (dashed line in patients with TNBC who achieved pCR (left) compared to those who did not (right), (B) Relative pre-treatment abundance of major immune cell populations in TNBC according to response to NAC, (C) Density plots showing higher density of CD8 + naïve T (dashed outline in top island) and CD4 + TEMRA cells (dashed outline in bottom island) in patients with luminal BC with minimal or no residual disease (RCB 0-I) versus moderate to extensive residual disease (RCB II-III) after NAC, (D) Relative pre-treatment abundance of CD4 + T cell subsets in luminal breast cancer according to response to NAC, (E) Relative pre-treatment abundance of CD8 + T cell subsets in luminal breast cancer according to response to NAC, (F) Density plots showing a trend towards higher density of B cells in patients with HER2 + who achieved pCR (left) compared to those who did not (right), (G) Relative pre-treatment abundance of major immune cell populations in HER2 + breast cancer according to response to NAC